Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
67.52 USD | -0.04% | +0.29% | +8.70% |
May. 16 | Axonics Implant Approved in Australia to Treat Overactive Bladders | MT |
May. 16 | Axonics, Inc. Receives Regulatory Approval for Recharge-Free SNM System in Australia | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+8.70% | 3.45B | |
+10.36% | 126B | |
-5.56% | 11.33B | |
+6.07% | 9.27B | |
+36.36% | 5.5B | |
-22.92% | 4.61B | |
-8.93% | 2.81B | |
-10.91% | 2.09B | |
-6.38% | 2.08B | |
-23.21% | 1.78B |
- Stock Market
- Equities
- AXNX Stock
- News Axonics, Inc.
- Leerink Partners Downgrades Axonics to Market Perform From Outperform, Sets Price Target at $71